D
Anixa Biosciences, Inc.
ANIX
$2.73
-$0.13-4.55%
D
Sell
10/16/2024Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 10/16/2024 due to an increase in the volatility index and total return index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 10/16/2024 due to an increase in the volatility index and total return index.
E
Sell
7/17/2024Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 7/17/2024 due to a large decline in the solvency index, total return index and growth index. The quick ratio declined from 14.57 to 13.95.
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 7/17/2024 due to a large decline in the solvency index, total return index and growth index. The quick ratio declined from 14.57 to 13.95.
D
Sell
5/24/2024Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 5/24/2024 due to an increase in the valuation index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 5/24/2024 due to an increase in the valuation index.
E
Sell
4/17/2024Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 4/17/2024 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0865 to -$0.1035, EBIT declined 18.29% from -$3.05M to -$3.61M, and operating cash flow declined 17.27% from -$1.97M to -$2.31M.
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 4/17/2024 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0865 to -$0.1035, EBIT declined 18.29% from -$3.05M to -$3.61M, and operating cash flow declined 17.27% from -$1.97M to -$2.31M.
D
Sell
8/23/2023Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 8/23/2023 due to a large increase in the solvency index and volatility index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 8/23/2023 due to a large increase in the solvency index and volatility index.
E
Sell
8/8/2023Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 8/8/2023 due to a decline in the volatility index, growth index and total return index.
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 8/8/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
7/21/2023Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 7/21/2023 due to an increase in the volatility index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D- from E+ on 7/21/2023 due to an increase in the volatility index.
E
Sell
7/6/2023Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 7/6/2023 due to a decline in the volatility index and total return index.
Anixa Biosciences, Inc. (ANIX) was downgraded to E+ from D- on 7/6/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index and total return index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index and total return index.
D
Sell
2/23/2023Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
D
Sell
2/8/2023Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 2/8/2023 due to a major decline in the solvency index, growth index and valuation index. The quick ratio declined from 21.55 to 14.57, EBIT declined 29.03% from -$2.8M to -$3.61M, and earnings per share declined from -$0.0902 to -$0.113.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 2/8/2023 due to a major decline in the solvency index, growth index and valuation index. The quick ratio declined from 21.55 to 14.57, EBIT declined 29.03% from -$2.8M to -$3.61M, and earnings per share declined from -$0.0902 to -$0.113.
D
Sell
5/5/2022Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index, total return index and growth index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index, total return index and growth index.
D
Sell
4/20/2022Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index and growth index. Operating cash flow declined 14.63% from -$1.04M to -$1.2M.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index and growth index. Operating cash flow declined 14.63% from -$1.04M to -$1.2M.
D
Sell
1/31/2022Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 1/31/2022 due to a decline in the volatility index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 1/31/2022 due to a decline in the volatility index.
D
Sell
1/14/2022Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 1/14/2022 due to a large increase in the growth index and valuation index. Operating cash flow increased 29.48% from -$1.48M to -$1.04M, EBIT increased 7.09% from -$4.39M to -$4.08M, and earnings per share increased from -$0.1423 to -$0.1336.
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 1/14/2022 due to a large increase in the growth index and valuation index. Operating cash flow increased 29.48% from -$1.48M to -$1.04M, EBIT increased 7.09% from -$4.39M to -$4.08M, and earnings per share increased from -$0.1423 to -$0.1336.
D
Sell
11/23/2021Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/5/2021Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 11/5/2021 due to a decline in the valuation index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 11/5/2021 due to a decline in the valuation index.
D
Sell
10/21/2021Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 10/21/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 10/21/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
8/30/2021Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 8/30/2021 due to a decline in the valuation index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 8/30/2021 due to a decline in the valuation index.
D
Sell
8/13/2021Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 8/13/2021 due to an increase in the total return index and valuation index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 8/13/2021 due to an increase in the total return index and valuation index.
D
Sell
7/29/2021Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 7/29/2021 due to a decline in the total return index and valuation index.
Anixa Biosciences, Inc. (ANIX) was downgraded to D from D+ on 7/29/2021 due to a decline in the total return index and valuation index.
D
Sell
6/11/2021Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 6/11/2021 due to a substantial increase in the total return index, solvency index and growth index. The quick ratio increased from 9.17 to 26.41, and earnings per share increased from -$0.0878 to -$0.0837.
Anixa Biosciences, Inc. (ANIX) was upgraded to D+ from D on 6/11/2021 due to a substantial increase in the total return index, solvency index and growth index. The quick ratio increased from 9.17 to 26.41, and earnings per share increased from -$0.0878 to -$0.0837.
D
Sell
5/20/2020Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 5/20/2020 due to a noticeable increase in the growth index and valuation index.
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 5/20/2020 due to a noticeable increase in the growth index and valuation index.
D
Sell
3/12/2020Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/12/2020 due to a major decline in the total return index, growth index and efficiency index. Operating cash flow declined 43.19% from -$1.34M to -$1.91M, net income declined 24.19% from -$2.09M to -$2.59M, and EBIT declined 23.55% from -$2.13M to -$2.63M.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/12/2020 due to a major decline in the total return index, growth index and efficiency index. Operating cash flow declined 43.19% from -$1.34M to -$1.91M, net income declined 24.19% from -$2.09M to -$2.59M, and EBIT declined 23.55% from -$2.13M to -$2.63M.
D
Sell
9/18/2019Upgraded
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 9/18/2019 due to an increase in the growth index, efficiency index and valuation index. Operating cash flow increased 55.39% from -$1.43M to -$640.1, earnings per share increased from -$0.1292 to -$0.1065, and EBIT increased 15.76% from -$2.59M to -$2.18M.
Anixa Biosciences, Inc. (ANIX) was upgraded to D from D- on 9/18/2019 due to an increase in the growth index, efficiency index and valuation index. Operating cash flow increased 55.39% from -$1.43M to -$640.1, earnings per share increased from -$0.1292 to -$0.1065, and EBIT increased 15.76% from -$2.59M to -$2.18M.
D
Sell
3/14/2019Downgrade
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/14/2019 due to a decline in the efficiency index, growth index and solvency index. Operating cash flow declined 30.23% from -$1.02M to -$1.33M, and total capital declined 0.77% from $5.18M to $5.14M.
Anixa Biosciences, Inc. (ANIX) was downgraded to D- from D on 3/14/2019 due to a decline in the efficiency index, growth index and solvency index. Operating cash flow declined 30.23% from -$1.02M to -$1.33M, and total capital declined 0.77% from $5.18M to $5.14M.
D
Sell
9/7/2018Upgraded
ITUS Corporation (ITUS) was upgraded to D from D- on 9/7/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.05 to 4.73.
ITUS Corporation (ITUS) was upgraded to D from D- on 9/7/2018 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.05 to 4.73.
D
Sell
5/24/2017Downgrade
ITUS Corporation (ITUS) was downgraded to D- from D on 5/24/2017 due to a significant decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.1197 to -$0.411, EBIT declined 56.35% from -$890.8 to -$1.39M, and operating cash flow declined 6.87% from -$683 to -$729.9.
ITUS Corporation (ITUS) was downgraded to D- from D on 5/24/2017 due to a significant decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.1197 to -$0.411, EBIT declined 56.35% from -$890.8 to -$1.39M, and operating cash flow declined 6.87% from -$683 to -$729.9.
D
Sell
1/23/2017Downgrade
ITUS Corporation (ITUS) was downgraded to D from D+ on 1/23/2017 due to a substantial decline in the total return index.
ITUS Corporation (ITUS) was downgraded to D from D+ on 1/23/2017 due to a substantial decline in the total return index.
D
Sell
12/27/2016Upgraded
ITUS Corporation (ITUS) was upgraded to D+ from D on 12/27/2016 due to a significant increase in the total return index, efficiency index and growth index. Total revenue increased 100% from $100 to $200, operating cash flow increased 16.17% from -$814.7 to -$683, and EBIT increased 7.81% from -$966.3 to -$890.8.
ITUS Corporation (ITUS) was upgraded to D+ from D on 12/27/2016 due to a significant increase in the total return index, efficiency index and growth index. Total revenue increased 100% from $100 to $200, operating cash flow increased 16.17% from -$814.7 to -$683, and EBIT increased 7.81% from -$966.3 to -$890.8.
D
Sell
11/28/2016Upgraded
ITUS Corporation (ITUS) was upgraded to D from D- on 11/28/2016 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 39.72% from -$1.35M to -$814.7, EBIT increased 14.71% from -$1.13M to -$966.3, and earnings per share increased from -$0.1456 to -$0.1262.
ITUS Corporation (ITUS) was upgraded to D from D- on 11/28/2016 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 39.72% from -$1.35M to -$814.7, EBIT increased 14.71% from -$1.13M to -$966.3, and earnings per share increased from -$0.1456 to -$0.1262.
D
Sell
8/11/2016Downgrade
ITUS Corporation (ITUS) was downgraded to D- from D on 8/11/2016 due to a decline in the total return index.
ITUS Corporation (ITUS) was downgraded to D- from D on 8/11/2016 due to a decline in the total return index.
D
Sell
7/21/2016Upgraded
ITUS Corporation (ITUS) was upgraded to D from D- on 7/21/2016 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.1825 to -$0.1456, and EBIT increased 19.81% from -$1.41M to -$1.13M.
ITUS Corporation (ITUS) was upgraded to D from D- on 7/21/2016 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.1825 to -$0.1456, and EBIT increased 19.81% from -$1.41M to -$1.13M.
D
Sell
3/11/2016Downgrade
ITUS Corporation (ITUS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
ITUS Corporation (ITUS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
D
Sell
2/19/2016Downgrade
ITUS Corporation (ITUS) was downgraded to D from D+ on 2/19/2016 due to a substantial decline in the efficiency index, growth index and solvency index. The quick ratio declined from 11.4 to 4.93, operating cash flow declined 33.61% from -$801.9 to -$532.4, and total capital declined 28.94% from $5.05M to $3.59M.
ITUS Corporation (ITUS) was downgraded to D from D+ on 2/19/2016 due to a substantial decline in the efficiency index, growth index and solvency index. The quick ratio declined from 11.4 to 4.93, operating cash flow declined 33.61% from -$801.9 to -$532.4, and total capital declined 28.94% from $5.05M to $3.59M.
D
Sell
12/24/2015Upgraded
ITUS Corporation (ITUS) was upgraded to D+ from D on 12/24/2015 due to a significant increase in the efficiency index.
ITUS Corporation (ITUS) was upgraded to D+ from D on 12/24/2015 due to a significant increase in the efficiency index.
D
Sell
8/28/2015Downgrade
ITUS Corporation (ITUS) was downgraded to D from D+ on 8/28/2015 due to a significant decline in the efficiency index and solvency index. Net income declined 28.37% from -$2.24M to -$1.6M, total capital declined 14.2% from $6.99M to $6M, and the quick ratio declined from 12.31 to 10.62.
ITUS Corporation (ITUS) was downgraded to D from D+ on 8/28/2015 due to a significant decline in the efficiency index and solvency index. Net income declined 28.37% from -$2.24M to -$1.6M, total capital declined 14.2% from $6.99M to $6M, and the quick ratio declined from 12.31 to 10.62.
D
Sell
6/16/2015Downgrade
ITUS Corporation (ITUS) was downgraded to D+ from C- on 6/16/2015 due to a decline in the valuation index.
ITUS Corporation (ITUS) was downgraded to D+ from C- on 6/16/2015 due to a decline in the valuation index.
C
Hold
6/1/2015Upgraded
ITUS Corporation (ITUS) was upgraded to C- from D+ on 6/1/2015 due to an increase in the volatility index, efficiency index and total return index.
ITUS Corporation (ITUS) was upgraded to C- from D+ on 6/1/2015 due to an increase in the volatility index, efficiency index and total return index.
D
Sell
3/25/2015Downgrade
ITUS Corporation (ITUS) was downgraded to D+ from C- on 3/25/2015 due to a noticeable decline in the growth index, total return index and valuation index.
ITUS Corporation (ITUS) was downgraded to D+ from C- on 3/25/2015 due to a noticeable decline in the growth index, total return index and valuation index.
C
Hold
3/10/2015Upgraded
ITUS Corporation (ITUS) was upgraded to C- from D on 3/10/2015 due to a significant increase in the efficiency index, growth index and valuation index. Total revenue increased 564.36% from $1.38M to $9.14M, and total capital increased 105.95% from $4.01M to $8.26M.
ITUS Corporation (ITUS) was upgraded to C- from D on 3/10/2015 due to a significant increase in the efficiency index, growth index and valuation index. Total revenue increased 564.36% from $1.38M to $9.14M, and total capital increased 105.95% from $4.01M to $8.26M.
D
Sell
1/30/2015Upgraded
ITUS Corporation (ITUS) was upgraded to D from D- on 1/30/2015 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 0.76 to 3.46, and debt to equity declined from 45.13 to 0.
ITUS Corporation (ITUS) was upgraded to D from D- on 1/30/2015 due to a significant increase in the solvency index and valuation index. The quick ratio increased from 0.76 to 3.46, and debt to equity declined from 45.13 to 0.
D
Sell
9/16/2014Downgrade
ITUS Corporation (ITUS) was downgraded to D- from D on 9/16/2014 due to a substantial decline in the solvency index and growth index. Earnings per share declined from -$0.0153 to $0.0018, EBIT declined 100.23% from -$1.28M to $2.9, and operating cash flow declined 33.58% from -$507.8 to -$337.3.
ITUS Corporation (ITUS) was downgraded to D- from D on 9/16/2014 due to a substantial decline in the solvency index and growth index. Earnings per share declined from -$0.0153 to $0.0018, EBIT declined 100.23% from -$1.28M to $2.9, and operating cash flow declined 33.58% from -$507.8 to -$337.3.
NASDAQ
04/01/2025 4:00PM Eastern
Quotes delayed
